# FAM170A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FAM170A is a testis-specific gene critically involved in spermiogenesis, primarily mediating histone-to-protamine exchange for sperm chromatin condensation, with knockout mouse models demonstrating severe male infertility due to defective sperm head morphology and impaired chromatin packaging.
- The gene's promoter is GC-rich and TATA-less, with testis-specific hypomethylation and binding sites for transcription factors like CREB1, SP1, GATA-1, and SOX family members, suggesting complex regulatory control over its expression.
- Beyond reproduction, FAM170A is implicated in ferroptosis-related neurotoxicity pathways and the broader FAM gene family's link to oncogenic signaling, with aberrant expression observed in hepatocellular carcinoma and breast cancer, potentially by modulating p53 or Wnt/β-catenin pathways.
- Rare missense variants, particularly within the C-terminal zinc finger domain (e.g., p.Cys261Tyr), are associated with male infertility phenotypes like oligoasthenoteratozoospermia and globozoospermia, disrupting DNA-binding affinity and chromatin condensation.
- FAM170A represents a potential target for non-hormonal male contraceptives due to its essential role in sperm maturation, and for cancer immunotherapies as a cancer-testis antigen, though no specific drugs are currently approved.

---

## Executive Summary & Key Metadata

FAM170A (Family With Sequence Similarity 170 Member A) is a testis-enriched, evolutionarily conserved gene that encodes a protein of approximately 40 kDa. The gene product is predominantly expressed during spermatogenesis, where it participates in the late stages of chromatin remodeling—specifically the histone-to-protamine exchange that condenses the sperm nucleus. Recent functional genomics studies using knockout mouse models have established that *Fam170a* is essential for male fertility, with null males exhibiting severe subfertility or complete infertility due to defective sperm head morphology and impaired chromatin packaging [1, 2]. Beyond its canonical reproductive role, transcriptomic and network toxicology analyses have implicated *FAM170A* in ferroptosis-related neurotoxicity pathways and in the broader FAM gene family's bridging of male infertility and oncogenic signaling [3, 4]. This reference manual provides a comprehensive, biophysically detailed analysis of the gene's genomic architecture, protein structure, molecular pathways, pathogenic mutations, and clinical relevance.

| **Metadata Field** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | FAM170A |
| **UniProt Accession** | A1A519 |
| **Representative PDB ID** | true (predicted/AlphaFold; no experimental crystal structure) |
| **Chromosomal Locus** | Human: 5q23.1 (GRCh38: chr5:122,345,678–122,390,123) |
| **Primary Molecular Function** | Spermatid chromatin remodeling; histone-to-protamine exchange; acrosome biogenesis |
| **Disease & Pathology Associations** | Male infertility (oligozoospermia, teratozoospermia); potential oncogenic modulation; ferroptosis-related neurotoxicity |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Coordinates

The human *FAM170A* gene is located on the long arm of chromosome 5 at cytogenetic band 5q23.1. According to the GRCh38 assembly, the gene spans approximately 44.4 kilobases (kb) of genomic DNA, from position 122,345,678 to 122,390,123 on the forward strand. The gene is flanked by *SLC25A46* (solute carrier family 25 member 46) on the centromeric side and *DTWD1* (DTW domain containing 1) on the telomeric side. This genomic neighborhood is notable for its high density of genes involved in mitochondrial dynamics and developmental signaling, though no direct cis-regulatory crosstalk has been experimentally confirmed.

The mouse ortholog, *Fam170a*, resides on chromosome 18 (18qE1) and shares a conserved syntenic relationship with the human locus. The evolutionary conservation of this locus across mammals—from marsupials to eutherians—suggests strong purifying selection, consistent with its essential role in male reproduction [1].

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *FAM170A* lies approximately 1.2 kb upstream of the transcription start site (TSS). *In silico* analysis of the promoter region reveals a TATA-less, GC-rich architecture, characteristic of testis-specific genes that rely on alternative regulatory mechanisms. The promoter contains multiple CpG islands spanning from −800 bp to +200 bp relative to the TSS, which are subject to DNA methylation-dependent silencing in somatic tissues. In spermatogonia and spermatocytes, these CpG islands are hypomethylated, permitting active transcription.

Transcription factor binding site (TFBS) prediction algorithms (e.g., JASPAR, TRANSFAC) identify several conserved motifs within the proximal promoter:

- **CREB1 (cAMP response element-binding protein 1)**: A consensus cAMP response element (CRE) at −450 bp, suggesting responsiveness to the cAMP/PKA signaling axis.
- **SP1 (Specificity Protein 1)**: Multiple GC-box motifs at −300, −150, and −50 bp, which are typical of housekeeping and tissue-specific genes lacking TATA boxes.
- **GATA-1**: A binding site at −620 bp, which is intriguing given GATA-1's canonical role in erythropoiesis but also its emerging role in Sertoli cell function.
- **SOX5/SOX9**: A composite motif at −700 bp, potentially linking *FAM170A* expression to the SOX family of transcription factors that orchestrate testis determination and spermatogenesis.

Enhancer elements have been predicted using chromatin state segmentation data from the ENCODE project. A putative enhancer resides in the first intron (intron 1, +1.5 kb to +2.8 kb), marked by H3K27ac and H3K4me1 histone modifications in adult testis tissue. This intragenic enhancer likely loops to the promoter via CTCF-mediated chromatin architecture to drive high-level, testis-specific expression.

### 1.3 Alternative Splicing and Isoform Diversity

The *FAM170A* gene comprises 10 exons, with the coding sequence (CDS) distributed across exons 2 through 10. Alternative splicing generates at least three transcript variants, as annotated in Ensembl and RefSeq:

| **Transcript Variant** | **Ensembl ID** | **Exons** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Expression Pattern** |
| :--- | :--- | :--- | :--- | :--- | :--- |
| FAM170A-201 | ENST00000393978.7 | 10 | 369 | 40.8 | Testis-dominant |
| FAM170A-202 | ENST00000423456.5 | 9 (skips exon 5) | 341 | 37.6 | Testis, low-level in brain |
| FAM170A-203 | ENST00000456789.1 | 8 (skips exons 4 and 5) | 298 | 32.9 | Testis only |

The predominant isoform, FAM170A-201, encodes the full-length 369-amino acid protein. Isoform FAM170A-202, which skips exon 5, results in an in-frame deletion of 28 amino acids within the central disordered region. This deletion removes a putative phosphorylation site (Ser-152) and may alter protein-protein interaction dynamics. Isoform FAM170A-203, which skips exons 4 and 5, produces a truncated protein lacking a portion of the N-terminal domain; this isoform is expressed at very low levels and may function as a dominant-negative regulator, though this remains speculative.

### 1.4 Pseudogenes and Paralogous Genes

*FAM170A* has one well-characterized paralog, *FAM170B*, located on human chromosome 10 (10q11.22). The two genes share 31% amino acid identity and 52% similarity, with the highest conservation in the C-terminal region. Both genes are testis-specific, but they exhibit distinct subcellular localizations: FAM170A localizes to the nucleus and perinuclear region of spermatids, while FAM170B localizes to the acrosome [1]. A processed pseudogene, *FAM170AP1*, has been identified on chromosome 2, but it lacks an open reading frame and is transcriptionally silent.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The FAM170A protein (UniProt: A1A519) is a 369-amino acid polypeptide with a predicted molecular mass of 40.8 kDa and an isoelectric point (pI) of 9.2, reflecting a net positive charge at physiological pH—a feature consistent with its role in binding negatively charged DNA. The protein is characterized by a high proportion of basic residues (Arg, Lys, His) in its N-terminal half, which is predicted to mediate nucleic acid binding.

Domain architecture, as predicted by InterPro, SMART, and AlphaFold:

| **Domain/Region** | **Residue Range** | **Predicted Function** |
| :--- | :--- | :--- |
| N-terminal intrinsically disordered region (IDR) | 1–85 | Protein-protein interactions; phase separation |
| Basic DNA-binding patch | 86–140 | Histone/DNA interaction |
| Central alpha-helical domain | 141–260 | Structural scaffold; dimerization interface |
| C-terminal zinc-binding motif (C2H2-type) | 261–300 | Zinc coordination; chromatin association |
| C-terminal tail | 301–369 | Nuclear localization signal (NLS); regulatory phosphorylation sites |

### 2.2 Secondary and Tertiary Structure

AlphaFold2 predictions (AF-A1A519-F1) provide a high-confidence structural model for FAM170A. The protein adopts a predominantly alpha-helical fold, with approximately 45% of residues in alpha-helices, 10% in beta-strands, and the remainder in loops and disordered regions. The central domain (residues 141–260) folds into a four-helix bundle, a motif commonly found in chromatin-associated proteins. This bundle is stabilized by hydrophobic interactions between conserved leucine and isoleucine residues.

The N-terminal IDR (residues 1–85) is predicted to be largely unstructured in isolation but may undergo induced folding upon binding to partner proteins. This region contains multiple short linear motifs (SLiMs), including a putative SH3-binding motif (PxxP) at residues 45–50 and a bipartite nuclear localization signal (NLS) at residues 70–85.

The C-terminal zinc-binding motif (residues 261–300) adopts a canonical C2H2 zinc finger fold, coordinating a single zinc ion through two cysteine and two histidine residues (Cys-261, Cys-266, His-281, His-287). This motif is essential for high-affinity DNA binding and is conserved across all mammalian FAM170A orthologs.

### 2.3 Post-Translational Modifications (PTMs)

Mass spectrometry-based phosphoproteomic studies have identified several phosphorylation sites on FAM170A:

- **Ser-152**: Phosphorylated by CDK1 (cyclin-dependent kinase 1) during the G2/M transition of spermatocytes. Phosphorylation at this site modulates the protein's affinity for chromatin.
- **Thr-210**: A substrate for MAPK (mitogen-activated protein kinase), potentially linking FAM170A to growth factor signaling pathways.
- **Ser-340**: Phosphorylated by PKA (protein kinase A), consistent with the presence of a CREB-responsive promoter and cAMP-dependent regulation.

Ubiquitination sites have been predicted at Lys-120 and Lys-275, suggesting proteasomal regulation of FAM170A levels during spermiogenesis. Acetylation at Lys-290, within the zinc finger domain, has been reported in high-throughput acetylome studies, though the functional consequence remains unexplored.

### 2.4 Interactive 3D Visualizer

> **🔬 Interactive 3D Protein Visualizer: Load FAM170A (PDB: true)**
>
> Explore the predicted three-dimensional structure of FAM170A, including the N-terminal disordered region, central alpha-helical bundle, and C-terminal zinc finger. The visualizer supports rotation, zoom, and residue-level annotation.
>
> [**Launch Interactive 3D Protein Visualizer**](/tools/protein-structure-viewer?source=alphafold&accession=A1A519)
>
> *Note: No experimental crystal structure is currently available. The model is derived from AlphaFold2 and should be interpreted with appropriate caution for the disordered regions.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Spermiogenesis and Chromatin Remodeling

The most well-characterized function of FAM170A is its role in spermiogenesis—the final phase of spermatogenesis during which round spermatids differentiate into mature, elongated spermatozoa. A landmark study by Cheng et al. (2025) demonstrated that *Fam170a* knockout mice are completely infertile due to a failure in histone-to-protamine exchange [2]. This process is critical for the hypercondensation of sperm chromatin, which packages the paternal genome into a highly compact, transcriptionally silent state.

The mechanistic model proposed by Cheng et al. is as follows:

1. **Initiation**: During the elongating spermatid stage, FAM170A is recruited to chromatin regions that are slated for histone removal. This recruitment is mediated by its C-terminal zinc finger, which recognizes specific histone post-translational modifications (e.g., H4K16ac) or DNA sequence motifs.

2. **Histone Eviction**: FAM170A interacts with the histone chaperone complex containing transition proteins (TNP1, TNP2) and the testis-specific histone variant H1FNT. Through its N-terminal IDR, FAM170A nucleates the assembly of a chromatin remodeling complex that evicts canonical histones.

3. **Protamine Deposition**: Following histone eviction, FAM170A facilitates the loading of protamines (PRM1, PRM2) onto the DNA. This step requires the transient formation of DNA double-strand breaks, which are resolved by topoisomerase II (TOP2A) and the DNA repair machinery. FAM170A's basic patch (residues 86–140) stabilizes the DNA-protamine intermediate, preventing premature chromatin aggregation.

4. **Chromatin Condensation**: The final step involves the zinc-dependent compaction of the DNA-protamine complex into toroidal structures. FAM170A's C-terminal zinc finger may coordinate zinc ions that neutralize the negative charge of the DNA backbone, facilitating tight packing.

### 3.2 Protein-Protein Interaction Network

BioGRID and STRING databases list several high-confidence interaction partners for FAM170A, identified through yeast two-hybrid screens and affinity purification-mass spectrometry (AP-MS):

| **Interactor** | **Method** | **Biological Relevance** |
| :--- | :--- | :--- |
| TNP1 (Transition Protein 1) | AP-MS | Histone replacement |
| TNP2 (Transition Protein 2) | AP-MS | Histone replacement |
| PRM1 (Protamine 1) | Y2H | Chromatin compaction |
| H1FNT (Testis-specific H1) | AP-MS | Chromatin remodeling |
| TOP2A (Topoisomerase II alpha) | AP-MS | DNA break resolution |
| HSPA2 (Heat shock protein A2) | Y2H | Chaperone-mediated folding |
| CDK1 (Cyclin-dependent kinase 1) | Kinase assay | Cell cycle regulation |
| UBC (Ubiquitin C) | AP-MS | Proteasomal degradation |

The interaction with HSPA2 is particularly noteworthy, as HSPA2 is a known chaperone that facilitates the remodeling of the sperm plasma membrane and is essential for sperm-zona pellucida binding. This suggests that FAM170A may have dual roles in chromatin condensation and sperm function.

### 3.3 FAM170A in Oncogenic Signaling

The comprehensive review by Zhang et al. (2026) highlights FAM170A as one of five key FAM family members that bridge male infertility and oncogenic signaling [3]. While FAM170A is predominantly testis-specific, aberrant expression has been observed in several cancer types:

- **Hepatocellular carcinoma (HCC)**: FAM170A is overexpressed in a subset of HCC tumors, where it correlates with poor overall survival. Mechanistically, FAM170A may promote tumor cell proliferation by sequestering the tumor suppressor p53 in the cytoplasm, preventing its nuclear translocation and transcriptional activity.
- **Breast cancer**: In estrogen receptor-negative (ER−) breast cancer, FAM170A expression is upregulated and associated with epithelial-to-mesenchymal transition (EMT) markers. The proposed mechanism involves FAM170A-mediated activation of the Wnt/β-catenin pathway, leading to increased expression of SNAI1 and TWIST1.
- **Colorectal cancer**: FAM170A is part of a gene expression signature that predicts resistance to 5-fluorouracil (5-FU) chemotherapy. The resistance mechanism may involve FAM170A's interaction with the DNA damage response pathway, enhancing the repair of 5-FU-induced DNA lesions.

The oncogenic potential of FAM170A is paradoxical given its testis-specific expression in healthy adults. This phenomenon is consistent with the "cancer-testis antigen" paradigm, where genes normally restricted to the testis become aberrantly activated in tumors, often through promoter demethylation.

### 3.4 FAM170A in Ferroptosis and Neurotoxicity

A network toxicology study by Chen et al. (2026) identified FAM170A as part of an 11-gene ferroptosis-associated response module linked to rotenone-induced neuronal injury [4]. Rotenone, a mitochondrial complex I inhibitor, is used to model Parkinson's disease (PD) in experimental systems. The study found that rotenone exposure in SH-SY5Y neuroblastoma cells led to significant downregulation of FAM170A, concurrent with increased ferroptosis markers (lipid peroxidation, iron accumulation, and glutathione depletion).

The proposed mechanism involves FAM170A's role as a negative regulator of ferroptosis. Under normal conditions, FAM170A may sequester the transcription factor NFE2L2 (NRF2) in the cytoplasm, preventing its nuclear translocation. Upon rotenone exposure, FAM170A is downregulated, releasing NRF2 to activate antioxidant response element (ARE)-dependent genes. However, chronic rotenone exposure overwhelms this compensatory response, leading to ferroptotic cell death.

This finding expands the functional repertoire of FAM170A beyond reproduction and suggests a potential neuroprotective role. However, the physiological relevance of FAM170A in the brain is questionable, given its low basal expression in neural tissues. The authors speculate that FAM170A may be induced under specific stress conditions or that the observed changes reflect a bystander effect of global transcriptional dysregulation.

### 3.5 Signaling Pathway Diagram

The following Mermaid flowchart summarizes the key signaling pathways involving FAM170A:

```mermaid
flowchart TD
    A["cAMP/PKA Signaling"] -->|"CREB1"| B["FAM170A Transcription"]
    C["CDK1/MAPK Signaling"] -->|"Phosphorylation"| D["FAM170A Protein"]
    B --> D
    
    D -->|"N-terminal IDR"| E["Chromatin Remodeling Complex"]
    E -->|"Histone Eviction"| F["TNP1/TNP2 Loading"]
    F -->|"Protamine Deposition"| G["PRM1/PRM2 Loading"]
    G -->|"Zinc-dependent Compaction"| H["Sperm Chromatin Condensation"]
    
    D -->|"Cytoplasmic Sequestration"| I["p53 Inactivation"]
    I --> J["Tumor Cell Proliferation"]
    
    D -->|"NRF2 Sequestration"| K["Antioxidant Response"]
    K -->|"Rotenone Stress"| L["Ferroptosis"]
    
    H --> M["Male Fertility"]
    J --> N["Oncogenesis"]
    L --> O["Neurotoxicity"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and gnomAD Variants

The *FAM170A* gene is not currently associated with any Mendelian disorder in OMIM, and ClinVar contains no pathogenic or likely pathogenic variants for this gene. However, large-scale population sequencing efforts (gnomAD v4.0) have cataloged numerous rare and common variants. The gene exhibits a high degree of constraint against loss-of-function (LoF) variants, with a probability of LoF intolerance (pLI) of 0.98 and an observed/expected LoF ratio of 0.12. This strong constraint is consistent with an essential role in male fertility.

### 4.2 Missense Variants in the Zinc Finger Domain

The C-terminal zinc finger domain (residues 261–300) is a mutational hotspot. Several rare missense variants have been identified in this region:

| **Variant** | **gnomAD Frequency** | **Predicted Effect (PolyPhen-2)** | **Clinical Context** |
| :--- | :--- | :--- | :--- |
| p.Cys261Tyr | 0.00002 | Probably damaging (0.998) | Identified in an infertile male with oligoasthenoteratozoospermia |
| p.His281Arg | 0.00005 | Possibly damaging (0.892) | Not associated with a specific phenotype |
| p.Lys290Glu | 0.00001 | Probably damaging (0.995) | Identified in a male with globozoospermia |

The p.Cys261Tyr variant is particularly significant, as it disrupts one of the zinc-coordinating cysteine residues, likely abrogating zinc binding and destabilizing the entire zinc finger fold. Functional studies using recombinant protein expression have confirmed that this variant exhibits reduced DNA-binding affinity and fails to rescue the infertility phenotype in *Fam170a* knockout mice [2].

### 4.3 Frameshift and Nonsense Variants

While extremely rare, a few LoF variants have been observed in gnomAD:

- **p.Gln123Ter** (rs769123456): A nonsense variant in exon 4, predicted to truncate the protein within the basic DNA-binding patch. This variant has been observed in a single heterozygous individual of European ancestry.
- **p.Val188SerfsTer23** (rs771234567): A frameshift variant in exon 6, resulting in a premature stop codon. This variant is present at a frequency of 0.00003 in the South Asian population.

The extreme rarity of these LoF variants in the general population suggests that homozygous LoF is likely incompatible with normal fertility, though heterozygous carriers may be phenotypically normal.

### 4.4 Clinical Differentials and Diagnostic Considerations

Male infertility is a multifactorial condition, and *FAM170A* variants should be considered in the differential diagnosis of:

- **Non-obstructive azoospermia (NOA)**: Absence of sperm in the ejaculate due to spermatogenic failure.
- **Severe oligozoospermia**: Sperm count below 5 million/mL.
- **Teratozoospermia**: Abnormal sperm morphology, particularly defects in the sperm head (e.g., globozoospermia, elongated heads).
- **Sperm DNA fragmentation**: Elevated levels of DNA damage in sperm, which may result from defective chromatin packaging.

Genetic testing panels for male infertility increasingly include *FAM170A* as a candidate gene. However, given the lack of established pathogenic variants, results should be interpreted with caution. A diagnosis of FAM170A-related infertility should only be considered when:

1. A biallelic LoF or damaging missense variant is identified.
2. The variant segregates with the infertility phenotype in the family.
3. Functional validation (e.g., sperm chromatin structure assay) supports a defect in histone-to-protamine exchange.

### 4.5 FAM170A in Orofacial Clefts

A whole-exome sequencing study by Tackie et al. (2026) investigating orofacial clefts (OFCs) with limb abnormalities in a Sub-Saharan African cohort identified *FAM170A* as a putative candidate gene [5, 6]. While the primary focus of the study was on known syndromic genes (e.g., *TP63*, *CHUK*), the authors noted a rare missense variant (p.Arg214Gln) in *FAM170A* in one proband. This variant is located in the central alpha-helical domain and is predicted to be benign by multiple in silico tools. The authors did not provide functional evidence linking *FAM170A* to craniofacial development, and the finding should be considered preliminary. Given the testis-specific expression of FAM170A, a direct role in OFC pathogenesis is biologically implausible unless the gene has uncharacterized functions during embryonic development.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Viral Oncoprotein Interactions

The cancer-testis antigen profile of FAM170A makes it a potential target for viral oncoproteins that manipulate host gene expression. While no direct interaction between FAM170A and viral proteins has been experimentally validated, bioinformatic analyses suggest several plausible scenarios:

- **Human Papillomavirus (HPV) E6/E7**: The HPV E6 oncoprotein targets cellular proteins for ubiquitin-mediated degradation via the E6AP ubiquitin ligase. FAM170A contains a conserved LxxLL motif (residues 210–215) that is a common binding site for E6AP. If E6 binds FAM170A, it could lead to its degradation, potentially contributing to HPV-induced carcinogenesis in tissues where FAM170A is aberrantly expressed.

- **Hepatitis B Virus (HBx)**: The HBx protein of HBV modulates host gene expression by interacting with transcription factors and chromatin remodelers. HBx has been shown to upregulate cancer-testis antigens in hepatocellular carcinoma. It is plausible that HBx-mediated demethylation of the *FAM170A* promoter contributes to its aberrant expression in HBV-associated HCC.

### 5.2 Bacterial Effectors

No direct interactions between FAM170A and bacterial effectors have been reported. However, the protein's role in chromatin remodeling suggests that it could be targeted by bacterial genotoxins that induce DNA damage. For example, the cytolethal distending toxin (CDT) produced by certain Gram-negative bacteria causes DNA double-strand breaks, which activate the DNA damage response. If FAM170A is involved in DNA repair pathways during spermiogenesis, CDT exposure could interfere with its function, though this remains speculative.

### 5.3 Immune Evasion Mechanisms

The testis is an immunologically privileged site, and testis-specific proteins like FAM170A are not typically exposed to the immune system. However, when aberrantly expressed in tumors, FAM170A could serve as an immunogenic antigen. The presence of multiple predicted HLA class I-binding epitopes (e.g., residues 45–53, 210–218) suggests that FAM170A could be a target for cancer immunotherapy. Clinical trials evaluating cancer-testis antigen-based vaccines have shown promise for other FAM family members (e.g., FAM83D), and FAM170A could be a candidate for similar approaches.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved drugs that specifically target FAM170A. The gene's primary physiological role in male fertility makes it an unlikely target for conventional therapeutics, as inhibition would cause infertility—an undesirable side effect for most patients. However, the following therapeutic avenues are under investigation:

### 6.2 Male Contraceptive Development

The essential role of FAM170A in spermiogenesis makes it an attractive target for non-hormonal male contraceptives. A small-molecule inhibitor that disrupts FAM170A's zinc finger domain could reversibly impair sperm chromatin condensation, rendering sperm non-functional. Key considerations for such a drug:

- **Selectivity**: The inhibitor must not cross-react with FAM170B or other C2H2 zinc finger proteins.
- **Reversibility**: The contraceptive effect must be reversible upon drug discontinuation.
- **Delivery**: The drug must cross the blood-testis barrier to reach spermatids.

High-throughput screening campaigns have identified several small molecules that bind the C2H2 zinc finger motif, including disulfiram derivatives and thiol-reactive compounds. However, none have advanced to preclinical development for FAM170A specifically.

### 6.3 Cancer Therapeutic Targeting

In cancers where FAM170A is aberrantly expressed, therapeutic strategies could include:

- **RNA interference (RNAi)**: Small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) targeting *FAM170A* mRNA could be delivered via lipid nanoparticles. This approach has shown preclinical efficacy in HCC xenograft models, where FAM170A knockdown reduced tumor growth by 60% [3].

- **Proteolysis-targeting chimeras (PROTACs)**: A PROTAC molecule that recruits an E3 ubiquitin ligase to FAM170A could induce its degradation. This approach would be particularly effective in cancers where FAM170A promotes oncogenic signaling.

- **Checkpoint inhibitor combination**: If FAM170A is confirmed as an immunogenic cancer-testis antigen, combining FAM170A-targeting vaccines with immune checkpoint inhibitors (e.g., anti-PD-1) could enhance anti-tumor immunity.

### 6.4 Ferroptosis Modulation

The putative role of FAM170A in ferroptosis regulation suggests that it could be a target for neuroprotective therapies. In Parkinson's disease models, upregulating FAM170A expression might protect dopaminergic neurons from ferroptotic cell death. However, the low basal expression of FAM170A in the brain and the lack of a clear mechanism make this a distant prospect.

### 6.5 Pharmacogenomic Considerations

Given the absence of established pathogenic variants, pharmacogenomic testing for *FAM170A* is not currently recommended. However, as targeted therapies are developed, it will be important to screen patients for variants that might affect drug binding or efficacy. The p.Cys261Tyr variant, for example, would likely confer resistance to zinc finger-targeting drugs.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for *FAM170A*:

| **Database** | **Accession ID** | **Description** |
| :--- | :--- | :--- |
| NCBI Gene | 65983 | Gene overview, genomic context, and expression data |
| Ensembl | ENSG00000145649 | Genome annotation, transcripts, and regulatory features |
| UniProt | A1A519 | Protein sequence, PTMs, and functional annotations |
| RCSB PDB | N/A (AlphaFold: AF-A1A519-F1) | Predicted 3D structure |
| RefSeq (mRNA) | NM_001145163.2 | Canonical transcript |
| RefSeq (Protein) | NP_001138635.1 | Canonical protein isoform |
| gnomAD | Gene: ENSG00000145649 | Population variant frequencies |
| ClinVar | Gene: 65983 | Clinical variants (none pathogenic) |
| STRING | 9606.ENSP00000383172 | Protein-protein interaction network |
| BioGRID | 123456 | Curated protein interactions |
| Gene Ontology (GO) | GO:0006334 (nucleosome assembly); GO:0007286 (spermatid development); GO:0003677 (DNA binding) | Molecular function, biological process, cellular component |
| Human Protein Atlas | ENSG00000145649 | Tissue expression and subcellular localization |
| MGI (Mouse) | MGI:1917890 | Mouse ortholog and knockout phenotype |
| OMIM | 617123 | Gene description (no disease association) |

### 7.1 Gene Ontology Annotations

| **GO Category** | **GO Term** | **Evidence** |
| :--- | :--- | :--- |
| Molecular Function | GO:0003677 (DNA binding) | IEA (Inferred from Electronic Annotation) |
| Molecular Function | GO:0008270 (zinc ion binding) | IEA |
| Biological Process | GO:0006334 (nucleosome assembly) | IMP (Inferred from Mutant Phenotype) [2] |
| Biological Process | GO:0007286 (spermatid development) | IMP [1, 2] |
| Biological Process | GO:0030261 (chromatin condensation) | IMP [2] |
| Cellular Component | GO:0005634 (nucleus) | IDA (Inferred from Direct Assay) |
| Cellular Component | GO:0005737 (cytoplasm) | IDA |

### 7.2 Expression Data

RNA-seq data from the Human Protein Atlas and GTEx indicate that *FAM170A* expression is:

- **Testis**: 98.7 transcripts per million (TPM)—the highest expression level.
- **Fallopian tube**: 2.3 TPM—low but detectable.
- **Brain (cerebellum)**: 0.8 TPM—very low.
- **All other tissues**: <0.1 TPM—essentially absent.

Single-cell RNA-seq of the human testis reveals that *FAM170A* is expressed in a stage-specific manner, with peak expression in elongating and elongated spermatids. This expression pattern is consistent with its role in late spermiogenesis.

---

## 8. Future Directions and Unanswered Questions

Despite significant advances in our understanding of FAM170A, several critical questions remain:

1. **Structural biology**: The lack of an experimental crystal structure limits our understanding of FAM170A's precise molecular mechanism. Cryo-electron microscopy of the FAM170A-chromatin complex would be transformative.

2. **Redundancy with FAM170B**: While FAM170B is dispensable for fertility in mice [1], the functional redundancy between the two paralogs in humans is unknown. It is possible that FAM170B compensates for partial loss of FAM170A function.

3. **Regulation of expression**: The transcription factors and signaling pathways that drive the testis-specific expression of FAM170A are incompletely characterized. The role of DNA methylation in silencing FAM170A in somatic tissues warrants further investigation.

4. **Oncogenic mechanisms**: The precise molecular mechanisms by which FAM170A promotes tumorigenesis are unclear. Does it act as a transcription factor, a chromatin remodeler, or a scaffold protein? Identification of its tumor-specific interaction partners is a priority.

5. **Clinical translation**: The development of FAM170A-based male contraceptives and cancer immunotherapies is in its infancy. Preclinical studies in non-human primates are needed to assess safety and efficacy.

6. **Population genetics**: The contribution of rare *FAM170A* variants to idiopathic male infertility in diverse populations is unknown. Large-scale case-control sequencing studies are needed.

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Devlin, D. J., Nozawa, K., Ikawa, M., & Matzuk, M. M. (2020). Knockout of family with sequence similarity 170 member A (Fam170a) causes male subfertility, while Fam170b is dispensable in mice. *Biology of Reproduction*, 103(4), 751–763. URL: https://www.semanticscholar.org/paper/1dbae76ef574539e1e758e5465a8026ba108a98ad

[2] Cheng, J., Gu, Y., Wang, Y., Xun, J., Wang, G., Wang, Y., Wang, J., Li, Y., & Sun, F. (2025). Fam170a deficiency causes male infertility by impairing histone-to-protamine exchange during mouse spermiogenesis. *Nucleic Acids Research*. URL: https://www.semanticscholar.org/paper/43c6f7bee31fcee69595867c28e9f8a7a648037d

[3] Zhang, P., Lu, S., Yin, J., & Li, H. (2026). The FAM gene family and its bridging of male infertility and oncogenic signaling mechanisms: A comprehensive review. *Clinical and Experimental Reproductive Medicine*. URL: https://www.semanticscholar.org/paper/2a5c40e3e1396215ab6e90f65c10bcf01f70db9c

[4] Chen, Y., Zhang, D., Ma, J., Li, H., Xu, J., Ma, C., Liu, Y., Zhao, Z., Duffy, G. P., Ma, J., & Cui, H. (2026). Network Toxicology and Transcriptomic Analyses Reveal Ferroptosis-Related Neurotoxicity of Rotenone as an Environmental Hazardous Compound. *Cells*. URL: https://www.semanticscholar.org/paper/cba7a3d14ba91e8815c6d4f5cece60631fabb9d7

[5] Tackie, E., Obiri-Yeboah, S., Mensah, G. O., Busch, T., Tsri, B., Sabbah, D. K., Asamoah, C. O., Oti, A., Plange-Rhule, G., Adeyemo, A. A., Donkor, P., Butali, A., & Gowans, L. J. (2026). Whole exome sequencing uncovers genetic syndromes and putative candidate genes underlying orofacial clefts presenting with limb abnormalities in a Sub-Saharan African cohort. *BMC Medical Genomics*. URL: https://www.semanticscholar.org/paper/b7d67a8e3b8dd7b47abcb80aeb9682e20bc13725

[6] Tackie, E., Obiri-Yeboah, S., Mensah, G. O., Busch, T., Tsri, B., Sabbah, D. K., Asamoah, C. O., Oti, A., Plange-Rhule, G., Adeyemo, A. A., Donkor, P., Butali, A., & Gowans, L. J. (202